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ARTICLE
Increased circulating levels of Factor H-Related
Protein 4 are strongly associated with age-related
macular degeneration
Valentina Cipriani 1,2,3,4,16*, Laura Lorés-Motta5,16, Fan He 6, Dina Fathalla 7, Viranga Tilakaratna6,
Selina McHarg6, Nadhim Bayatti6, İlhan E. Acar 5, Carel B. Hoyng5, Sascha Fauser8,9, Anthony T. Moore2,3,10,
John R.W. Yates2,3,11, Eiko K. de Jong 5, B. Paul Morgan7,17, Anneke I. den Hollander 5,12,17,
Paul N. Bishop6,13,17 & Simon J. Clark 6,14,15,17*
Age-related macular degeneration (AMD) is a leading cause of blindness. Genetic variants
at the chromosome 1q31.3 encompassing the complement factor H (CFH, FH) and CFH
related genes (CFHR1-5) are major determinants of AMD susceptibility, but their molecular
consequences remain unclear. Here we demonstrate that FHR-4 plays a prominent role in
AMD pathogenesis. We show that systemic FHR-4 levels are elevated in AMD (P-value=
7.1 × 10−6), whereas no difference is seen for FH. Furthermore, FHR-4 accumulates in the
choriocapillaris, Bruch’s membrane and drusen, and can compete with FH/FHL-1 for C3b
binding, preventing FI-mediated C3b cleavage. Critically, the protective allele of the
strongest AMD-associated CFH locus variant rs10922109 has the highest association with
reduced FHR-4 levels (P-value= 2.2 × 10−56), independently of the AMD-protective
CFHR1–3 deletion, and even in those individuals that carry the high-risk allele of rs1061170
(Y402H). Our findings identify FHR-4 as a key molecular player contributing to comple-
ment dysregulation in AMD.
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Age-related macular degeneration (AMD) is the mostcommon cause of vision loss in Western societies1. Softdrusen are an early sign of AMD. These deposits form
within Bruch’s membrane (BrM) underneath the retinal pigment
epithelium (RPE) basement membrane and contain apolipopro-
tein B and E, cholesterol-rich lipoproteins that are thought to be
derived from the RPE2. In addition, they contain a variety of
other proteins, with complement proteins being a prominent
component3. This early stage of disease can then progress to late
AMD, manifesting as either geographic atrophy (‘dry’ AMD) or
choroidal neovascularization (‘wet’ AMD)4.
AMD has a strong genetic basis; associations with 45 common
single-nucleotide polymorphisms (SNPs) and 7 rare variants
across 34 genetic loci have been reported in the largest genome-
wide association study (GWAS) to date, explaining ~34% of
AMD risk5. Many of these variants reside in genes encoding
complement system components, particularly those encoded at
the regulators of complement activation (RCA) locus on chro-
mosome 1q31.3, including factor H (FH; CFH) and FH-related
1–5 (CFHR1–5)6,7. Common SNPs within CFH, including
rs1061170 encoding a tyrosine to histidine substitution at posi-
tion 402 (Y402H), were first identified as major susceptibility
variants for AMD8–11. The recent largest GWAS established
eight independent signals (four common variants, four rare) over
578 Mb of the RCA locus5. Except for the highly penetrant CFH
missense variant R1210C12 and synonymous variant rs35392876
in CFH, all variants are non-coding: four intronic in CFH (2),
CFHR5 (1) and KCNT2 (1) and two intergenic (8 kb upstream
CFH/35 kb downstream KCNT2; 14 kb downstream CFHR1/156
kb upstream CFHR4). The role of these genes in the pathogenesis
of AMD is unclear.
The CFH gene encodes FH and its smaller splice variant, FH-
like 1 (FHL-1)13,14. FH is the main plasma complement regulator,
but FHL-1 predominates in BrM and choriocapillaris6,15. While
FH/FHL-1 downregulate complement activation in plasma and
on surfaces, the FHR proteins can compete with FH/FHL-1 for
surface and ligand binding, thus disrupting their negative reg-
ulatory function and facilitate local activation16,17 (see Fig. 3 of
ref. 17 for an explanatory diagram of CFH and CFHR genes and
the structures of FH, FHL-1 and FHR proteins). However, due to
the extremely high level of sequence homology shared by all
of the FHR proteins17, it has thus far remained difficult to
investigate their individual tissue expression patterns. Rare AMD-
associated coding variants in CFH and their functional con-
sequences directly implicate FH in the pathogenesis of
AMD5,12,18–22. The molecular basis of the association of FH/
FHL-1 402H variant to AMD pathology has been reported to
involve altered binding to heparan sulfate, C-reactive protein or
malondialdehyde, impacting local complement activation and
subretinal inflammation23–26. Downstream of CFH, a common
∼84 kb deletion of CFHR3 and CFHR1 and a rare ∼120 kb
deletion encompassing CFHR1 and CFHR4 are associated with
reduced AMD risk, supporting the hypothesis that multiple genes
at the locus may be involved in AMD27–34. In line with the
genetic findings, dysregulation of the complement system in the
eye and blood has been reported in the early stages of AMD
predominating in the extracellular matrix (ECM) surrounding the
fenestrated capillaries of the choriocapillaris that underlies
BrM35–38.
A recent GWAS identified an intronic variant in CFHR4 that
associated with increased systemic complement activation and
AMD risk39. Furthermore, it has recently been reported that the
top AMD-associated CFH variant rs109221095 is associated with
altered CFHR4 expression in the liver40. Taken together, these
studies propose that, as well as FH, FHR-4 may also be involved
in AMD. Having recently generated a novel, specific monoclonal
antibody (mAb) against FHR-4, here we investigate, using a
combination of biochemical, immunohistochemical and genetic
approaches, whether FHR-4 directly impacts AMD pathogenesis.
We show, in two large, independent cohorts, that blood FHR-4
levels are elevated in AMD patients compared to controls. FHR-4
is present in areas of pathology in AMD retina, co-localizing with
complement activation products. In vitro functional analyses
show that FHR-4 binds C3 fragments and competes out the
binding of the regulatory proteins FH and FHL-1. Genetic asso-
ciation analyses show that several of the established AMD risk
variants at the CFH locus are associated with FHR-4 levels in the
blood, a finding strongly supported by haplotype association
analyses. Taken together, our findings implicate FHR-4 as a key
driver of complement dysregulation in the AMD retina.
Results
Systemic FHR-4 levels are elevated in advanced AMD cases.
Systemic FHR-4 concentrations were measured in plasma and
serum samples of 484 late AMD patients (geographic atrophy and/
or choroidal neovascularization) and 522 phenotyped controls,
collected within two independent AMD studies (Cambridge and
European Genetic Database (EUGENDA); Table 1). AMD patients
had significantly elevated FHR-4 levels compared to controls, in
each study separately (β= 0.18 and P value= 0.016 for Cambridge
and β= 0.19 and P value= 1.7 × 10−4 for EUGENDA; Wald test)
and in the two-cohort meta-analysis (β= 0.19, 95% confidence
interval (CI) 0.11–0.27 and P value= 7.1 × 10−6) (Table 1 and
Fig. 1a). Association of FHR-4 levels stratified by type of end-stage
disease, that is, choroidal neovascularization (CNV) only and
geographic atrophy (GA) only, was additionally performed. These
analysis showed comparable estimates in both cohorts (CNV only:
β= 0.15 and P value= 0.068 for Cambridge and β= 0.18 and
P value= 0.001 for EUGENDA; GA only: β= 0.20 and P value=
0.099 for Cambridge and β= 0.45 and P value= 0.008 for
EUGENDA; Wald test) and in the meta-analysis (CNV only: β=
0.17, CI 0.09–0.26 and P value= 9.3 × 10−5; GA only: β= 0.28, CI
0.09–0.47 and P value= 0.004), with wider CIs for the GA-only
group reflecting the smaller sample size (62 GA-only cases in
Cambridge and 10 GA-only cases in EUGENDA). The overall
adjusted odds ratio (OR) of advanced disease for an FHR-4
increase of 1 standard deviation was 1.37 (CI= 1.19–1.58;
P value= 1.8 × 10−5) (Supplementary Fig. 1a). We also measured
systemic FH levels and found no significant difference between
patients and controls (P values 0.959, 0.535 and 0.704 for Cam-
bridge, EUGENDA and meta-analysis, respectively; Table 1, Fig. 1b
and Supplementary Fig. 1b).
CFHR4 is expressed in the liver but not in the eye. We found no
evidence of transcription of the CFHR4 gene in primary human
RPE cells by reverse transcription PCR (Supplementary Fig. 2a).
Analysis of the Gene Expression Omnibus datasets (https://www.
ncbi.nlm.nih.gov/geo) confirmed absence of CFHR4 transcription
in the neurosensory retina, RPE and choroid using Affymetrix
U133plus2 human genome arrays41, Affymetrix Human Exon 1.0
ST arrays42,43 or RNA sequencing44,45 (Supplementary Fig. 2b–f).
Analysis of gene expression across 53 human tissues from the
Genotype-Tissue Expression project (https://www.ebi.ac.uk/gxa/
home)46 demonstrated that CFHR4 expression was restricted to
the liver (Supplementary Fig. 2g).
FHR-4 in the choriocapillaris is associated with complement
activation. Immunostaining demonstrated that FHR-4 accumu-
lates in the intercapillary septa, the extracellular matrix (ECM)
between the fenestrated capillaries of the choriocapillaris
(Fig. 2a–c) and within BrM (Fig. 2c). Diffusion experiments
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demonstrated that FHR-4 does not completely transit this ECM
(Supplementary Fig. 3). Drusen, a hallmark of AMD, were
strongly positive for FHR-4 Ab labelling (Fig. 2d). C3b also
localized to the choriocapillaris intercapillary septa and appeared
to co-localize with FHR-4 (Fig. 2e). FHR-4 is reported to bind
C3b and stabilize the C3 convertase47,48. We confirmed that
FHR-4 binds immobilized C3b (Fig. 2f) and demonstrated that
FHR-4 competes with the negative regulators, FH and FHL-1, for
binding immobilized C3b (Fig. 2g). The consequences of this
were modelled in vitro employing C3b α-chain cleavage assays
(Fig. 2h and Supplementary Fig. 4). C3b was incubated with FHL-
1 and factor I (FI) titrated to give ~80% C3b α-chain cleavage;
FHR-4 inhibited α-chain cleavage in a dose-dependent manner; a
2.5-fold molar excess of FHR-4 over FHL-1 caused 50% reduction
in cleavage (Fig. 2i).
CFH locus AMD risk variants associate with FHR-4 levels. The
International AMD Genomics Consortium (IAMDGC) GWAS5
reported eight independently associated variants at the CFH locus
(Fig. 3a and Supplementary Data 1). We repeated single-variant
association analyses with AMD in the Cambridge and
EUGENDA samples (originally part of the IAMDGC dataset) and
observed all ORs with the same direction and similar magnitude
as in IAMDGC at all variants, except for rare variant rs191281603
(Supplementary Data 1).
We hypothesized that one or several of the established AMD
risk variants at the CFH locus are associated with increased
systemic FHR-4 levels. The rare CFH variant R1210C12, present
heterozygously in a single case from the Cambridge cohort (with
corresponding values of FHR-4 and FH levels equal to 5.7 and
296.4, respectively), was excluded from this analysis. The top
(rs10922109, 1.1), second (rs570618, 1.2; proxy for Y402H), fifth
(rs187328863, 1.5) and sixth (rs61818925, 1.6) IAMDGC hits at
the CFH locus showed strong associations with FHR-4 levels
(after Bonferroni correction for multiple testing), with direction
of allelic effect on levels concordant with that on disease for all
variants (Table 2, Fig. 3b, Supplementary Data 2 and
Supplementary Fig. 5). The strongest allelic effect on FHR-4
levels was seen at the top IAMDGC variant rs10922109, with
β=−0.42 and P value= 2.2 × 10−56 (Wald test) for the minor
allele A associated with decreased disease risk. In the Cambridge
and EUGENDA cohorts, respectively, this finding translates
into (back-log transformed) FHR-4 levels expressed as geo-
metric mean values [95% CIs] equal to 7.7 μg ml−1 [7.0–8.5] and
8.5 μg ml−1 [7.9–9.1] in CC genotype individuals, 5.5 μg ml−1
[5.0–6.1] and 6.0 μg ml−1 [5.7–6.4] in AC genotype individuals
and 3.2 μg ml−1 [2.5–4.0] and 3.6 μg ml−1 [3.3–3.9] in AA
genotype individuals. Analogous single-variant association
analyses with FH levels revealed a significant association only
at rs10922109 and rs61818925 with much smaller effect size
(β= 0.03 and −0.03, respectively) (Table 2, Supplementary
Data 2 and Supplementary Fig. 5).
To assess whether genetic variants at loci other than CFH
associated with systemic FHR-4 levels, we performed a subsidiary
(hypothesis-free) GWAS meta-analysis of FHR-4 levels. A single
~1Mb region spanning the extended CFH locus
(chr1q31.3:196,240,335–197,281,307) showed genome-wide sig-
nificant (P ≤ 5 × 10−8) associations with FHR-4 levels (Fig. 4a,
Supplementary Fig. 6a and Supplementary Data 3 and Supple-
mentary Data 4). The top signal rs7535263 is in tight linkage
disequilibrium (LD) (R2= 0.98, D′= 1.00) with the top
IAMDGC variant rs10922109 (1.1) (regional plot in Fig. 4a,
Supplementary Data 5; OR= 0.11, P value= 1.7 × 10−612 in
IAMDGC5). Analogous GWAS meta-analysis of FH levels also
revealed a single genome-wide significant association confined toT
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variants in tight LD in a ~150 kb region at the CFH locus
(chr1q31.3:196,674,714–196,825,287; including rs6677604, a
proxy for the previously reported AMD protective CFHR1–3
deletion29) (Fig. 4b, Supplementary Fig. 6b, Supplementary
Data 6, Supplementary Data 7 and Supplementary Data 8), but
effect on FH levels was limited (β=−0.10, P value= 2.4 × 10−11,
Wald test, at the top variant rs74696321). Notably, the intronic
AMD risk variant rs6685931 in CFHR4 (LD with rs10922109:
R2= 0.43, D′= 0.96), associated with complement activation in
the recent GWAS39, was strongly associated with levels of FHR-4
(β= 0.28, P value= 2.3 × 10−25, Wald test), but not FH (β=
0.005, P value= 0.607, Wald test).
40
P = 0.016
P = 0.959 P = 0.535
P = 1.7 × 10–4
FHR-4 levels by AMD status
FH levels by AMD status
30
20
FH
R
-4
10
0
800
a
b
600
400FH
200
0
Control, Cambridge Control, EUGENDACase, Cambridge Case, EUGENDA
Control, Cambridge Control, EUGENDACase, Cambridge Case, EUGENDA
Fig. 1 Systemic FHR-4 levels are elevated in AMD patients. a shows box plots (and corresponding data points) of FHR-4 levels measured in two separate
AMD cohorts: Cambridge (plasma from 214 controls and 304 late AMD cases) and EUGENDA (serum from 308 controls and 180 late AMD cases). AMD
patients show statistically significantly elevated FHR-4 levels compared to controls. Geometric mean FHR-4 levels were: Cambridge, 5.5 µg ml−1 in controls
vs. 6.6 µgml−1 in cases; EUGENDA, 6.0 µg ml−1 in controls vs. 7.2 µg ml−1 in cases. These differences remained significant after adjustment for sex, age,
batch effects and first two genetic principal components (P value= 0.018 and 8.4 × 10−5 for Cambridge and EUGENDA, respectively; Wald test). b shows
box plots (and corresponding data points) of FH levels measured in the same samples, where no statistically significant difference between cases and
controls was observed: Cambridge, 349.0 µg ml−1 in controls vs. 348.6 µg ml−1 in cases; EUGENDA, 304.7 µg ml−1 in controls vs. 308.7 µg ml−1 in cases.
Each box plot depicts median value (central line), first quartile (lower bound line) and third quartile (upper bound line). Source data are provided as a
Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14499-3
4 NATURE COMMUNICATIONS |          (2020) 11:778 | https://doi.org/10.1038/s41467-020-14499-3 | www.nature.com/naturecommunications
CFH locus haplotypes strongly associate with AMD and FHR-4
levels. To assess the combined effect of variants at the CFH locus,
we carried out association analyses of the haplotypes formed by
the seven CFH variants considered in our study with AMD and
FHR-4/FH levels; we included rs6677604 as proxy for the
CFHR1–3 deletion29 to assess its influence on FHR-4/FH levels.
The rare CFHR1-4 deletion33,34 was present heterozygously in
three controls and one advanced AMD patient and was not
included in this analysis. Haplotype associations with AMD were
also assessed in the whole IAMDGC dataset5.
We observed nine common haplotypes with overall
frequency ≥1% (Fig. 5b and Supplementary Data 9). The
most frequent haplotype CTTGCCGC (H1; controls 32%,
cases 49% in IAMDGC) that carries the disease risk allele of
the proxy for Y402H (1.2) was used as reference. Common
H2–H5 and rarer H7 haplotypes carried significantly lower
AMD risk than H1, while rarer H6 (TTTGCCGC) and H9
(CTTGCTGC) carried higher risk than H1; H8 (CTTGCCTC)
did not show a significantly different risk from H1 (Fig. 5a and
Supplementary Data 9). Similar OR estimates were observed
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in our two-cohort meta-analysis (Fig. 5a and Supplementary
Data 9).
Haplotypes H2 (CTGGACTC) and H3 (CTGAACGC) strongly
associated with decreased FHR-4 levels and carry independent
effects with no overlapping CIs (β=−0.49, P value= 1.7 × 10−44
and β=−0.25, P value= 4.4 × 10−10, respectively; Wald test)
(Fig. 5a and Supplementary Data 9). While both haplotypes carry
the FHR-4-lowering/AMD-protective alleles A of rs10922109
(1.1) and G of rs570618 (1.2), H2 carries the FHR-4-lowering/
AMD-protective allele T of rs61818925 (1.6) and H3 carries the
FHR-4-lowering/AMD-protective allele A of rs6677604, tag for
the AMD-protective CFHR1–3 deletion. Neither of the haplotypes
showed a more significant association with FHR-4 levels than the
meta-analysis single-variant associations (Table 2). Analogous
haplotype association analyses with FH levels revealed a
significant association only at H2 (after Bonferroni correction)
with small effect (β= 0.07, P value= 3.3 × 10−6, Wald test).
Results for the diplotype (haplotype pair) association analyses are
shown in Supplementary Data 10 and Supplementary Fig. 7.
Remarkably, among the genotypes that contain one copy of H1
(Y402H), diplotypes H1:H2, H1:H3 and H1:H7 showed a
significantly lower AMD risk (OR= 0.33, P value= 5.3 × 10−152,
OR= 0.29, P value= 1.0 × 10−161 and OR= 0.42, P value=
2.2 × 10−24, respectively, in IAMDGC; Wald test) and decreased
levels of FHR-4 (β=−0.54, P value= 2.0 × 10−16, β=−0.31,
P value= 8.0 × 10−6 and β=−0.54, P value= 0.001, respectively,
in our two-cohort meta-analysis), compared to reference H1:H1
genotype.
Using a sequential forward approach, we tested the association
of the haplotypes formed by rs10922109 (1.1) and rs61818925
(1.6), the best two single-variant association signals with FHR-4
levels in our meta-analysis (Table 2). The most frequent
haplotype CG (H1*; controls 44%, cases 64% in IAMDGC)
was used as reference. We observed three other haplotypes
(H2*–H4*) carrying both distinct AMD lower risk (in IAMDGC;
with similar OR estimates in our two-cohort meta-analysis) and
distinct lowering effects on FHR-4 levels (Fig. 6a–c and
Supplementary Data 11). Haplotype H2* (AT) showed the
strongest association with FHR-4 levels (β=−0.52, P value=
2.4 × 10−58, Wald test) with a larger effect size and more
significant P value than any of the single-variant signals (Table 2).
Haplotype H4* (AG) was the only haplotype also associated
with FH levels (β= 0.08, P value= 7.7 × 10−7, Wald test).
Adding SNP rs570618 (1.2), the third meta-analysis single-
variant association signal with FHR-4 levels (Table 2), to the
inferred haplotypes did not significantly improve the dissection
of the genetic effects on FHR-4 levels at the CFH locus
(lowest P value= 2.0 × 10−53, Wald test, at haplotype GAT with
β=−0.50).
Discussion
Here we provide compelling evidence to show that AMD is
associated with genetically driven elevated circulating levels of
FHR-4 and not associated with circulating FH levels. FHR-4 likely
predisposes to disease by penetrating the ECM of the chor-
iocapillaris and BrM and acting locally by facilitating complement
activation. FHL-1 is the complement regulator primarily
responsible for protecting intercapillary septa ECM from com-
plement activation6,15, but this protective function may be
inhibited by FHR-4. FHR-4 accumulates in the intercapillary
septa of the choriocapillaris, the ECM surrounding the fene-
strated capillaries and a major site of AMD pathogenesis
(Fig. 2a–e). CFHR4 gene transcription was absent in the RPE and
choroid, demonstrating that the systemic circulation is the source
of FHR-4 in the eye. Deposition of C3b in the intercapillary septa
will result in C3 convertase formation, complement activation
and inflammation unless sufficiently regulated by FI-mediated
C3b breakdown in the presence of FHL-115. Based on our in vitro
competition assays (Fig. 2j), we propose that in AMD the accu-
mulation of FHR-4 in the ECM out-competes FHL-1 for C3b
binding, thereby preventing FI-mediated C3b breakdown and
driving complement activation. FHR-4 bound to deposited C3b
may also directly facilitate C3 convertase formation47,48. Exces-
sive complement turnover, driven by FHR-4 accumulation, will
continue to recruit and activate circulating immune cells49,
another key feature of early AMD. Quite how complement over-
activation leads to drusen formation remains unclear, although
studies have demonstrated that a combination of both comple-
ment over-activation and oxidative stress can result in lipid
accumulation in RPE cells and BrM50. Furthermore, non-
canonical roles of complement have also been shown to influ-
ence the ability to clear apolipoproteins from RPE cells and BrMs
in various animal models51.
Remarkably, the CFH locus was the only genome-wide sig-
nificant locus in our GWAS meta-analysis of FHR-4 levels. The
top signal is in tight LD with the strongest published AMD
association signal at the CFH locus5 (Fig. 4a, Supplementary
Fig. 6a and Supplementary Data 3, Supplementary Data 4 and
Supplementary Data 5). The triangular relationship between
established susceptibility CFH locus variants, FHR-4 levels and
AMD provides strong support for the association we observe
between FHR-4 levels and increased AMD risk (Table 1, Fig. 1a
and Supplementary Fig. 1a) to be causal. Our haplotype-based
association analyses allowed the individual effects of FHR-4
levels, the CFHR1-3 deletion and the Y402H variant of FH/FHL-1
to be dissected. Using the most frequent haplotype H1 (carrying
the risk allele of Y402H) as reference, the two most protective
haplotypes, H2 and H3, were associated with the lowest levels of
FHR-4 (Fig. 5a–b and Supplementary Data 9). The H2 haplotype
Fig. 2 Accumulation of FHR-4 in the choriocapillaris inhibits C3b breakdown. a shows a schematic diagram illustrating anatomical structures in the
macula including the retinal pigment epithelium (RPE), the underlying Bruch’s membrane (BrM) and the intercapillary septa within the choriocapillaris;
basement membranes are represented as black lines. Drusen, hallmark lesions of early AMD, form within BrM underneath the RPE basement membrane.
b, c Immunohistochemistry showing the localization of FHR-4 (yellow) predominantly in the intercapillary septa: weak labelling is also seen within BrM.
Collagen IV staining is used to delineate basement membranes, which define the inner and outer borders of BrM (red); DAPI labelling is in blue. FHR-4 is
also localized in drusen (d); the RPE is absent from these tissue sections. e Both FHR-4 and C3/C3b localize in the intercapillary septa of the
choriocapillaris (white arrow): scale bars 20 μm. SPR analysis showing the binding of FHR-4 to immobilized C3b (f). Solid-phase binding assays
demonstrate that FHR-4 can compete off fluid-phase FH or FHL-1 binding to immobilized C3b (g). Measurement of FHL-1-mediated breakdown of C3b by
factor I (h); in the presence of fixed concentrations of C3b and factor I, increasing concentrations of FHL-1 result in increased breakdown of the C3b α-chain
(see Supplementary Fig. 4 for full gel image). i optimal C3b breakdown conditions from h are repeated, but now include increased concentrations of fluid-
phase FHR-4, where an inhibition of FHL-1/FI-mediated C3b α-chain breakdown is observed (see Supplementary Fig. 4 for full gel image). j FHR-4 prevents
FHL-1 acting as a cofactor for factor I, this results in the formation of a C3 convertase and the activation of the amplification loop of complement and
subsequent inflammation. Data in g–i are from n= 3, averaged from three independent experiments ± s.e.m. Source data are provided as a Source Data file.
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Fig. 3 Four AMD risk variants at the CFH locus are strongly associated with FHR-4 levels. Schematic diagram of chromosome 1 showing the genes in the
CFH locus and the genomic location of the eight established AMD risk variants from the large IAMDGC GWAS of AMD5 and rs6677604, a proxy for the
previously reported AMD-protective CFHR1–3 deletion29 (a). Variant annotations are in red or blue depending on whether the corresponding minor allele is
AMD deleterious or protective. The rare missense variant rs121913059 (1.3; R1210C) was only present heterozygously in a case individual from the
Cambridge cohort, and therefore was not included in the genetic association analyses with the FHR-4/FH levels. b shows box plots (and corresponding
data points) of FHR-4 levels by AMD status and SNP genotype for the four variants that showed significant associations (after Bonferroni correction) with
FHR-4 levels (Table 2), in the Cambridge and EUGENDA cohorts combined. Each box plot depicts median value (central line), first quartile (lower bound
line) and third quartile (upper bound line). Source data are provided as a Source Data file.
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(carrying the FHR-4-lowering/AMD-protective alleles A of
rs10922109 (1.1) and T of rs61818925 (1.6)) does not contain the
CFHR1–3 deletion, suggesting that lower FHR-4 levels confer the
disease-protective effect. Furthermore, the diplotype analysis
demonstrates that the H1:H2 genotype is associated with disease-
protection relative to H1:H1, suggesting a dominant decreased
disease risk effect of lower FHR-4 levels even in the presence of
the Y402H risk variant on the other allele (Supplementary
Data 10 and Supplementary Fig. 7). Finally, we showed that the
two independently AMD-associated variants rs10922109 (1.1)
and rs61818925 (1.6) are a minimal set of variants that explain
the genetic effect on FHR-4 levels at the CFH locus (Fig. 6a–c).
FH levels were not different between cases and controls in our
two independent cohorts (Fig. 1b and Supplementary Fig. 1b).
Previous studies have measured systemic levels of FH in AMD
and reported inconsistent results52–60. The sample size of our
analysis (484 cases and 522 controls) exceeds all previous inves-
tigations. Our GWAS meta-analysis of FH levels reveals a similar
genetic structure to that previously reported52, with the top signal
in high LD with variants that tag the common CFHR1–3 deletion
(Fig. 4b, Supplementary Fig. 6b, Supplementary Data 6, Supple-
mentary Data 7 and Supplementary Data 8). The data also show
that systemic FH and FHR-4 levels are dictated by a different
genetic architecture (Supplementary Fig. 8). The top signal for FH
levels, rs74696321 (β=−0.10, P value=2.4 × 10−11), is only
among the genome-wide significant association tail for FHR-4
levels (653th hit, P value= 7.4 × 10−9) with opposite direction of
allelic effect (β= 0.23), while the top signal for FHR-4 levels,
rs7535263 (β=−0.42, P value= 9.0 × 10−57), tagging the top
AMD-associated variant rs10922109, does not pass the genome-
wide significance threshold in the GWAS meta-analysis of FH
levels (β= 0.03, P value= 0.005). It should be noted that the
circulating levels of FHR-4 are clearly associated with AMD risk,
but the molar ratios of FHR-4 and FH/FHL-1 in blood are not
representative of the ratios of the accumulated proteins in the
ECM of the choriocapillaris and BrM. This can be attributed to
the relatively large hydrodynamic size of FH compared to FHR-4
and FHL-1; we have previously shown that there is more FHL-1
in the tissue than FH, and that FH, unlike FHL-1, cannot diffuse
across BrM15,61. Furthermore, the absence of local FHR-4
expression in the eye emphasizes the relevance of systemic
levels of this protein for its accumulation in the choriocapillaris,
whereas FHL-1, and any FH that is present, may be derived
locally or systemically.
Genetically driven variations in the levels and functions of
alternative pathway complement proteins play a central role in
AMD pathogenesis. Common and rare coding variants in CFH
are important: the common Y402H variant and a majority of the
rare variants in CFH identified to date (that generally result in a
familial, early-onset condition) affect the function of both FHL-1
and FH, suggesting a particular role for FHL-1 in AMD
pathogenesis62,63. However, there are rare variants affecting only
FH, including the R1210C mutation, strongly associated with
early-onset AMD, showing that full-length FH also has an
important role12. In addition, mutations in CFI and common
variants in C3 and CFB modify AMD risk5,64. Therefore, it can be
concluded that a balance between the actions of proteins that
inhibit the alternative pathway (FH/FHL-1, FI) and those that
activate the alternative pathway (C3, FB) influence AMD risk.
Here we provide compelling data suggesting another regulator of
the alternative pathway, FHR-4, is likely to have an important
role in regulating this balance and thereby modifying AMD risk.
This research implies that targeting FHR-4 may represent a future
therapeutic avenue to explore in the treatment of AMD. Our
demonstration that high systemic FHR-4 levels are associated
with AMD risk makes the case for a therapy that lowers systemicT
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Fig. 4 GWAS meta-analysis of FHR-4 levels reveals a strong signal spanning the CFH locus. Each panel shows a Manhattan plot, a regional plot (upper
left-hand side) and a quantile–quantile (QQ) plot (upper right-hand side) for the results of the GWAS meta-analysis of FHR-4 levels (a) and FH levels (b).
Manhattan plots illustrate P values (Wald test) for each single variant tested for association with log(levels). Observed −log10(P values) are plotted against
the genomic position of each variant on chromosomes 1–22 plus the X chromosome. The horizontal red line indicates the threshold considered for genome-
wide significance (P value≤ 5 x 10−8). Regional plots show the only genome-wide association signal observed, that is, at the CFH locus (on chromosome
1q31.3). The most associated variant is denoted by a purple circle and is labelled by its rsID. The other surrounding variants are shown by circles coloured
to reflect the extent of LD with the most associated variant (based on 1000 Genomes data, November 2014). A diagram of the genes within the relevant
regions is depicted below each plot. Physical positions are based on NCBI RefSeq hg19 human genome reference assembly. QQ plots compare the
distribution of the observed test statistics with its expected distribution under the null hypothesis of no association. A marked departure from the null
hypothesis (reference line) is seen in the meta-analysis of FHR4 levels. Genomic inflation values (λ) were equal to 1.008 and 1.005 from the GWASs of
FHR-4 levels and 1.002 and 1.014 from the GWASs of FH levels, in the Cambridge and EUGENDA studies, respectively.
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FHR-4 levels; this could be achieved using Abs or other agents
that block or sequester the protein or by anti-sense targeting of
hepatic FHR-4 synthesis. The efficacy of clinical trials evaluating
FHR-4 inhibiting treatments could be enhanced by patient
selection based on FHR-4 levels and the genetic markers
identified here.
Methods
Study samples. The Cambridge AMD study is a case–control study with subjects
recruited from the southeast and northwest of England between 2002 and 200665.
All affected subjects had CNV and/or GA. Controls were spouses, partners or
friends of index patients. Blood samples were obtained at the time of interview;
EDTA and lithium–heparin plasma samples were used for DNA extraction and
FHR-4/FH measurements, respectively. The EUGENDA created for clinical and
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molecular analysis of AMD comprises late AMD cases and controls recruited at
Radboud University Medical Centre, the Netherlands, and University of Cologne,
Germany. Details on exclusion criteria and grading are provided in the Supple-
mentary Methods. All participants provided written informed consent for clinical
examination, epidemiological data collection and blood sampling for biochemical
and genetic analyses. Serum and plasma samples were used for FHR-4/FH mea-
surements. Donor eye tissue was obtained from Manchester Eye Tissue Repository
(ethically approved Research Tissue Bank, UK NHS Health Research Authority ref.
15/NW/0932). The banked tissue was collected and stored within 48 h of death;
there was prior informed consent for research use. Human Tissue Act 2004 (UK)
guidelines were followed. For all studies, ethical approval was obtained from either
national or local ethics committees (NRES Committee East Midlands – Derby for
the Cambridge AMD study; Arnhem–Nijmegen Commissie Mensgebonden
Onderzoek (CMO) and Ethics Commission of Cologne University’s Faculty of
Medicine for EUGENDA) and adhered to the tenets of the Declaration of Helsinki.
Proteins and Abs. Recombinant FHR-4 was made through the GenScript gene
synthesis and protein expression service (Piscataway, NJ, USA) using their
baculovirus-insect cell expression system and was based on the published sequence
for the FHR-4B variant of the CFHR gene (UniProt identifier Q92496-3): the
protein was designed to include an N-terminal 6×His tag and TEV cleavage site
(Supplementary Fig. 9).
For the generation of specific FHR-4 mAbs, mice were immunized
subcutaneously with recombinant FHR-4 (~30 µg/mouse) in complete Freund’s
adjuvant; boosted 4 and 6 weeks later with FHR-4 (dose as above) in incomplete
Freund’s adjuvant and test bled at 8 weeks. Mice with the highest titre in a
screening assay on immobilized FHR-4 protein were selected and boosted
intraperitoneally with FHR-4 (30 µg in phosphate-buffered saline (PBS)), sacrificed
48 h later and the spleen harvested aseptically. Spleen cells, obtained by perfusion
with RPMI in a sterile cabinet, were fused with SP2 myeloma cells to generate
hybridomas using standard protocols. Cells were plated at limiting dilution in 96-
well plates and left undisturbed for 14 days. Supernatant (50 µl) was removed from
each well and screened for anti-FHR-4 titre as above. Positive clones were subjected
to three rounds of re-cloning prior to expansion and large-scale culture. Abs were
purified on protein G and tested in Western blotting against recombinant FHR-4
and human serum. Non-competitive pairs of Abs were identified for enzyme-linked
immunosorbent assay (ELISA) development.
Recombinant FHL-1 was expressed in HEK293 cells as described previously15.
Commercially available purified complement proteins used include C3b (VWR
International, Lutterworth, UK, catalogue no. 204860), FH (Sigma-Aldrich,
catalogue no. C5813), and FI (VWR International, catalogue no. 341280).
Commercially available Ab against collagen IV was used (catalogue no: 600-401-
106S, 2B Scientific Ltd., Oxford, UK).
FHR-4 and FH systemic level measurements. The levels of FHR-4 were mea-
sured using an optimized in-house sandwich ELISA. Nunc-Immuno™ MaxiSorp™
96-well plates were coated with 50 µl per well of monoclonal anti-FHR-4 Ab 4E9 at
5 µg ml−1 (in 0.1 M carbonate buffer pH 9.6). After blocking in 2% bovine serum
albumin (BSA) in PBS+ 0.1%Tween-20 (PBST), plates were washed in PBST and a
dilution series of purified FHR-4 protein diluted in 0.1% PBST added to wells in
duplicate to generate a standard curve. Test samples were added (50 µl per well)
in duplicate at a 1:40 dilution to the remaining wells, and plates were incubated at
37 °C for 1.5 h. Plates were washed in PBST, 50 µl per well of 1 µg ml−1 of horse
radish peroxidase (HRP)-labelled anti-FHR-4 mAb clone 17 was added and the
plates were incubated for 1 h at room temperature. After washing, 50 µl per well of
orthophenylenediamine (SIGMAFAST™ OPD, Sigma-Aldrich, UK) was added to
develop the plates and the reaction was stopped after 5 min by adding an equal
volume of 10% sulfuric acid. Absorbance was measured in a plate reader at 492 nm
and protein concentrations were interpolated from the standard curve plotted
using GraphPad Prism 5.
FH levels were measured in a similar manner using monoclonal anti-FH Ab
OX24 at 5 µg ml−1 as capture, purified FH protein diluted in 0.1% PBST as
standard, test samples at a 1:4000 dilution, HRP-labelled monoclonal anti-FH Ab
35H9 (1 µg ml−1) as the detection antibody, developed with OPD and read
as above.
Immunohistochemistry. Human donor eye tissue sections were obtained from the
Manchester Eye Tissue repository where 5 mm biopsies of the macula region from
donor eyes were frozen in OCT and undergone cryo-sectioning (10 μm) that were
subsequently stored at −80 °C. Frozen tissue section slides were stained for the
presence of FHR-4, collagen IV or C3/C3b using methods described previously15.
Briefly, tissue sections were incubated with chilled (−20 °C) histological grade
acetone:methanol (1:1, v/v; Sigma-Aldrich) for 20 s before thorough washing with
PBS. Tissue sections were blocked with 0.1% (w/v) BSA, 1% (v/v) goat serum, and
0.1% (v/v) Triton X-100 in PBS for 1 h at room temperature. After washing, tissue
sections were incubated with Ab combinations of either 10 μg ml−1 of anti-FHR-4
mAb (clone 150) mixed with either 1 μg ml−1 anti-Collagen IV rabbit polyclonal
Ab, or 1 μg ml−1 anti-C3/C3b rabbit polyclonal antibody (catalogue no: 21337-1-
AP, Proteintech Group Inc., United States), for 16 h at 4 °C. Sections were washed
and biotinylated anti-mouse immunoglobulin G (IgG) (catalogue no. BA_9200,
Vector laboratories Inc.) diluted 1:250 in PBS was applied for 1 h to amplify the
FHR-4 signal. Slides were subsequently washed and Alexa Fluor® 647 streptavidin
(catalogue no: S32357, Invitrogen) diluted 1:250 in PBS and Alexa Fluor® 488-
conjugated goat anti-rabbit Ab (Invitrogen, USA) diluted 1:500 in PBS were added
for 2 h at room temperature. After washing, DAPI (4′,6-diamidino-2-phenylindole)
was applied as a nuclear counterstain (at 0.3 mM for 5 min) prior to mounting with
medium (Vectashield; H-1400, Vector Laboratories, Peterborough, UK) and
application of a coverslip.
In the case of blank control sections, an identical protocol was followed, but
PBS replaced the primary antibody. To test antibody specificity in
immunohistochemistry, pre-adsorption experiments were performed whereby 10-
fold molar excess of recombinant FHR-4 is premixed with the anti-FHR-4 mAb
prior to application to the tissue sections (Supplementary Fig. 10). Further testing
was performed by pre-absorbing with excess purified FHL-1 protein to ensure the
anti-FHR-4 antibody did not cross-react (Supplementary Fig. 10). Furthermore,
competition ELISAs were performed demonstrating the specificity of clone 150 for
FHR-4 and not FH (Supplementary Fig. 11). In all cases images were collected on a
Zeiss AxioImager D2 upright microscope using a ×40/0.5 EC Plan-neofluar and
×100/0.5 EC Plan-neofluar objective and captured using a Coolsnap HQ2 camera
(Photometrics) through Micromanager software v1.4.23. Specific band pass filter
sets for DAPI, FITC and Cy5 were used to prevent bleed through from one channel
to the next. Images were then processed and analysed using Fiji ImageJ (http://
imagej.net/Fiji/Download).
Surface plasmon resonance. The binding of FHR-4 to immobilized C3b was
measured by surface plasmon resonance using a Biacore 3000 (GE Healthcare).
The sensor surfaces were prepared by immobilizing human C3b onto the flow cells
of a Biacore series S carboxymethylated dextran (CM5) sensor chip (GE Health-
care) using standard amine coupling and included blank flow cells where no C3b
protein was present. Experiments were performed at 25 °C and a flow rate of 15 μl
min−1 in PBS with 0.05% surfactant P20. FHR-4 was injected in triplicate at
concentrations ranging from 1 to 100 μg ml−1. Samples were injected for 150 s and
dissociated for another 200 s; the chip was regenerated with 1M NaCl for 1 min
and re-equilibrated into PBS with 0.05% surfactant P20 prior to the next injection.
After subtraction of the blank cell value from each response value, association and
dissociation rate constants were determined by global data analysis. All curves were
Fig. 5 Haplotype analysis identifies CFH locus haplotypes strongly associated with AMD and FHR-4 levels. a Illustrates the association of the observed
common nine haplotypes formed by the seven AMD-associated CFH locus variants considered in our association analyses and rs6677604 (overall
haplotype frequency ≥1% in the Cambridge and EUGENDA cohorts combined, accounting for 98.5% of 2012 chromosomes) with AMD and with FHR-4/
FH levels. Details of the alleles forming the haplotypes together with the frequency distribution in the two cohorts combined, and as estimated in the
IAMDGC dataset5 (16,144 patients with advanced AMD and 17,832 controls of European ancestry), are shown in b: haplotype CTTGCCGC (H1) that
carries the AMD increasing-risk allele T of the proxy for Y402H (1.2) is used as reference (coloured in red); alleles that are different from the reference are
coloured in blue; the direction of association with AMD for the minor allele of each single variant as estimated in the IAMDGC study5 is indicated within
parentheses. Four association plots are displayed in a: the first two (top) plots show the OR (with CI) estimates for the CFH haplotype association with
AMD in the IAMDGC dataset and our two-cohort meta-analysis, respectively; the third and fourth (bottom) plots show the β (with CI) estimates for the
CFH haplotype association with FHR-4 and FH levels, respectively, in our two-cohort meta-analysis; haplotype H1 is used as reference. The estimates
shown in each plot are labelled further to indicate the presence of alleles that differ from the reference; those alleles are indicated with the IAMDGC
association signal numbers of the corresponding variants (1.1, 1.5–1.7), in red to indicate that the allele different from the reference is AMD risk-increasing
allele, in blue if protective; the Y402H label is blue to indicate the presence of the protective allele G of variant 1.2, red for the AMD risk-increasing allele T;
finally, the label DEL indicates the presence of the protective allele A of the proxy for the CFHR1-3 deletion (rs6677604). See Supplementary Data 9 for full
details of the haplotype association estimates. Source data are provided as a Source Data file.
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fitted using a 1:1 Langmuir association/dissociation model (BIAevaluation 4.1; GE
Healthcare).
Solid-phase binding assays. Purified C3b was adsorbed onto the wells of
microtiter plates (Nunc Maxisorb, Kastrup, Denmark) at 1 μg per well in 100 μl per
well PBS for 16 h at room temperature. Plates were blocked for 90 min at 37 °C
with 300 μl per well 1% (w/v) BSA in standard assay buffer (SAB; 20 mM HEPES,
130 mM NaCl, 0.05% (v/v) Tween-20, pH 7.3). SAB was used for all subsequent
incubations, dilutions and washes and all steps were performed at room tem-
perature. A constant concentration of 100 nM was made for either FH or FHL-1 in
SAB and increasing concentrations of FHR-4 are used as competitor, up to 500 nM.
FH/FHR-4 and FHL-1/FHR-4 mixes were incubated with the immobilized C3b for
4 h. After washing, bound FH or FHL-1 protein was detected by the addition of
100 μl per well of 0.5 μg ml−1 OX23 antibody and incubated for 30 min, followed
by washing and a 30-min incubation in 100 μl of a 1:1000 dilution of AP-
conjugated anti-mouse IgG (Sigma-Aldrich). Plates were developed using 100 μl
per well of a 1 mg ml−1 disodium p-nitrophenylphosphate solution (Sigma-
Aldrich) in 0.05M Tris-HCl, 0.1 M NaCl, pH 9.3. The absorbance values at 405 nm
were determined after 10 min of development at room temperature and corrected
against blank wells (i.e., those with no immobilized C3b).
Fluid-phase C3b breakdown assays. The fluid-phase cofactor activity of FHL-1
was measured by incubating purified FHL-1, C3b and FI together in a total volume
of 20 μl PBS for 15 min at 37 °C. For each reaction 2 μg C3b and 0.04 μg FI were
used with varying concentrations of FHL-1 ranging from 0.015 μg to 1 μg per
reaction. The assay was stopped by the addition of 5 μl 5× sodium dodecyl sulfate
(SDS) reducing sample buffer and boiling for 10 min at 100 °C. Samples were
run on a 4–12% NuPAGE Bis Tris gel at 200 V for 60 min in order to maximize
the separation of the C3b breakdown product bands (Supplementary Fig. 4).
Molecular weight markers used were Novex Sharp pre-stained protein standards
(3.5–260 kDa, catalogue no. LC5800, Life Technologies, Paisley, UK). The density
of the 68 kDa iC3b product band was measured using ImageJ64 (version 1.40g; rsb.
info.nih.gov/ij) and used to track C3b breakdown efficiency of the FHL-1 proteins.
For FHR-4 inhibition assays, the amount of FHL-1 used in the reaction is fixed at
1 μg and increasing amounts of FHR-4 were added to create up to a 5-fold molar
excess of FHR-4 over FHL-1. Otherwise, the reactions were performed under the
same condition as previously. In all cases averaged data from three separate
experiments were used.
Ussing chamber diffusion experiments. The macular region of enriched BrM
isolated from donor eyes was mounted in an Ussing chamber (Harvard Apparatus,
Hamden, CT)61. Once mounted, the 5-mm-diameter macular area was the only
barrier between two identical compartments (Supplementary Fig. 3). Both sides of
BrM were washed with 2 ml PBS for 5 min at room temperature. Fresh PBS was
placed in both the sample and diffusate chambers. To the sample chamber, pure
recombinant FHR-4, final concentration of 100 μg ml−1, was added and the Ussing
chamber was left at room temperature for 24 h with gentle stirring in each com-
partment to avoid generating gradients of diffusing protein. Samples from each
chamber were analysed on 4–12% NuPAGE Bis-Tris gels, run at 200 V for 60 min.
Either 20 μl samples straight from each chamber were mixed with 5 μl 5× SDS
loading buffer and run or 100 μl samples were taken and concentrated using
StrataClean beads (hydroxylated silica; Agilent Technologies, Cheadle, UK) for
5 min at room temperature before centrifugation. Beads were then re-suspended in
20 μl neat 5× SDS loading buffer and loaded directly to the gel. Gels were stained
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Fig. 6 The AMD-associated variants rs10922109 (1.1) and rs61818925
(1.6) are a minimal set of variants that explain the genetic effect on FHR-
4 levels at the CFH locus. a illustrates the association of the observed four
haplotypes formed by the two independently AMD-associated variants
rs10922109 (1.1) and rs61818925 (1.6) at the CFH locus with AMD and with
FHR-4/FH levels. Variants 1.1 and 1.6 represent the best two single-variant
association signals with FHR-4 levels in the Cambridge and EUGENDA
meta-analysis (Table 2). Details of the alleles forming the haplotypes
together with the frequency distribution in the two cohorts combined (484
patients with advanced AMD and 522 controls) and as estimated in the
IAMDGC dataset5 (16,144 patients with advanced AMD and 17,832
controls of European ancestry) are shown in c: most common haplotype CG
(H1*) is used as reference (coloured in red); alleles that are different from
the reference are coloured in blue; the direction of association with AMD
for the minor allele of each single variant as estimated in the IAMDGC
study5 is indicated within parentheses. Four association plots are displayed
in a: the first two (top) plots show the OR (with CI) estimates for the CFH
haplotype association with AMD in the IAMDGC dataset and our two-
cohort meta-analysis, respectively; the third and fourth (bottom) plots
show the β (with CI) estimates for the CFH haplotype association with FHR-
4 and FH levels, respectively, in our two-cohort meta-analysis; haplotype
H1* is used as reference. The estimates shown in each plot are labelled
further to indicate the presence of alleles that differ from the reference;
those alleles are indicated with the IAMDGC association signal numbers of
the corresponding variants (1.1 and 1.6), in blue to indicate that the allele
different from the reference is AMD protective. See Supplementary Data 11
for full details of the rs10922109–rs61818925 haplotype association
estimates. Finally, b shows box plots (and corresponding data points) of
FHR-4 levels (top) and FH levels (bottom) by rs10922109–rs61818925
haplotype for each study cohort (Cambridge and EUGENDA). Each box plot
depicts median value (central line), first quartile (lower bound line) and
third quartile (upper bound line). Source data are provided as a Source
Data file.
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with Instant Blue stain (Expedeon, Harston, UK) for 60 min at room temperature,
before washing and storage in MiliQ water. Molecular weight markers used were
Blue Prestained Protein Standards, Broad Range (11–190 kDa, New England Bio-
Labs, Hitchin, UK, catalogue no. P7706S). Diffusion experiments were performed
on three separate donor BrM.
Genotype data and association analysis. All individuals included in this study
had been previously genotyped with a custom-modified Illumina HumanCoreEx-
ome array at the Centre for Inherited Disease Research (CIDR) and analysed
within the IAMDGC GWAS (43,566 subjects; 16,144 advanced AMD cases and
17,832 controls of European ancestry in the primary analysis dataset)5. Quality
control and genotype imputation using the 1000 Genomes Project66 reference
panel were performed by the IAMDGC as described previously5. A total of
9,618,989 quality-controlled common (minor allele frequency (MAF) ≥1%) var-
iants (289,971 genotyped; 9,329,018 imputed) were available for the 1006 indivi-
duals included in this study. Phased genotype data as inferred within the IAMDGC
study5 were also available and used in the haplotype-based association analyses. All
statistical association analyses were conducted on each cohort separately (Cam-
bridge and EUGENDA), and combined as two-stage, fixed-effects meta-analyses of
the available individual participant data from the two cohorts. Heterogeneity across
studies was assessed using the I2 statistic. FHR-4 and FH levels were natural
logarithmically transformed to ensure normality of the distribution when using
linear regression models. We assessed the association of late AMD with natural
logarithmically transformed FHR-4/FH levels via Wald tests using linear regression
models adjusted for sex, age, batch effects and the first two genetic principal
components (as estimated within the IAMDGC study5). We also reported the
association of FHR-4/FH levels with late AMD via OR expressed as per standard
deviation (SD) change of log levels using logistic regression models adjusted for
sex, age, batch effects and the first two genetic principal components. We assessed
the association of the eight independently AMD-associated variants at the CFH
locus reported by the IAMDGC study5 (i.e., rs10922109 [1.1], rs570618 [1.2],
rs121913059 [1.3], rs148553336 [1.4], rs187328863 [1.5], rs61818925 [1.6],
rs35292876 [1.7], rs191281603 [1.8]; Supplementary Data 1) with natural loga-
rithmically transformed FHR-4/FH levels via Wald tests on the variant genotypes
coded as 0, 1 and 2 according to the number of minor alleles for the directly typed
variants or allele dosages for the imputed variants, using linear regression models
adjusted for sex, age, batch effects and the first two genetic principal components in
controls, and in all samples further adjusting for AMD status. The single-SNP
association with AMD was assessed with ORs expressed as per 1 minor allele, using
logistic regression models adjusted for the first two genetic principal components.
Finally, we extracted the best-guess (i.e., most likely) haplotypes formed by the
AMD-associated variants at the CFH locus considered in our analysis and addi-
tionally included rs6677604 as proxy for the AMD-protective CFHR1–3 deletion29,
using the phased genotype data produced within the IAMDGC study5. The asso-
ciation of the observed haplotypes with AMD was assessed using logistic regression
models adjusted for the first two genetic principal components, and with FHR-4/
FH levels using linear regression models adjusted for AMD status, sex, age, batch
effects, and the first two genetic principal components. The haplotype-based
association with AMD was also performed on the whole IAMDGC primary ana-
lysis dataset of 16,144 patients with advanced AMD and 17,832 control subjects of
European ancestry using logistic regression models adjusted for whole-genome
amplification and the first two genetic principal components as per the IAMDGC
study5. All the statistical analyses above were conducted using the Stata software,
version 13.1 (StataCorp); tobit command was used for censored regression models
to take into account any ‘below of detection’ FHR-4 levels (n= 16 data points equal
to baseline 0.504116; with virtually identical results as per regress command for
linear regression models); ipdmetan and mvmeta commands were used for con-
ducting meta-analyses of individual participant data.
We also carried out GWASs of natural logarithmically transformed FHR-4
and FH levels in controls from each cohort (Cambridge and EUGENDA) using
linear regression models adjusted for sex, age, batch effects and the first two
genetic principal components, and in all samples further adjusting for AMD
status. The GWASs were carried out using the EPACTS software (http://genome.
sph.umich.edu/wiki/EPACTS) and Wald tests were performed on the variant
genotypes coded as 0, 1 and 2 according to the number of minor alleles for the
directly typed variants or allele dosages for the imputed variants. Genomic
control correction67 was applied if λ was >1. Effect size estimates and standard
errors of single variants seen in both cohorts were subsequently combined in a
fixed-effect meta-analysis using METAL68. This meta-analysis had a statistical
power of over 80% to detect associations of genetic variants with a MAF ≥1%
explaining ≥3.9% of the variance in FHR-4 levels (Genetic Power Calculator:
http://zzz.bwh.harvard.edu/gpc/). Manhattan and Q–Q plots were generated
using the qqman R package (version 0.1.2). Regional plots of association were
generated using LocusZoom (version v0.4.8)69. Finally, LD measures (R2 and D′)
were calculated using LDlink (https://ldlink.nci.nih.gov/), based on the
European (EUR) population genotype data originates from Phase 3 (Version 5)
of the 1000 Genomes Project66.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The summary statistics for the GWAS meta-analyses of FHR-4 and FH levels are
available through the UCL Research Data Repository at https://rdr.ucl.ac.uk/ [https://doi.
org/10.5522/04/11396565].
The Gene Expression Omnibus datasets used for the gene expression analyses are:
GSE18811; GSE41102; GSE50195; GSE94437; GSE99248. The Genotype-Tissue
Expression (GTEx) Project datasets used for the gene expression analyses were obtained
from the GTEx Portal, https://gtexportal.org/home/multiGeneQueryPage (4/4/2018),
dataset dbGaP accession number phs000424.v8.p2; the GTEx Project was supported by
the Common Fund of the Office of the Director of the National Institutes of Health, and
by NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS. The source data underlying Figs. 1,
2b–i, 3b, 4, 5a, 6a, b and Supplementary Figs. 2a, 5, 6, 7a–d, 8, 10a, 11 are provided as a
Source Data file. All other datasets and reagents generated/used in the current study are
available from the corresponding authors upon reasonable request.
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